Developing tomorrow's cancer therapies. Today. invIOs is a private biotech company focusing on discovery and development of novel cancer therapeutics that empower and educate the immune system to fight cancer. We leverage our deep expertise in immune-system activation to advance a focused pipeline of individualized and targeted approaches against solid tumors. Our focus is on earlier-stage development, with a sweet spot in bringing assets through discovery and pre-clinical development and into clinical trials. We launched in 2022 as a spin-out bundling the innovative oncology assets of APEIRON Biologics. Our highly motivated team of 35 people has deep expertise across the …

163 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣 Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide. We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform. Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide. - Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies) - We overcome limitations of …

160 similar entities Type: Startup Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

A clinic-ready biotech developing human cell-derived secretome drugs to cure inflammation-related pathologies Med’Inn’Pharma (MIP) is a clinic-ready Biotech company that was founded in 2017 as a spin-off from the French blood bank establishment (EFS) and of the French National Institute of Health (INSERM). MIP is a pioneer in developing a new class disease modifying therapies dedicated to resolve pathologic inflammation in a wide range of degenerative diseases and conditions. Our founders are world leaders in immunology and inflammation-resolution, and have developed a patent protected process to harness bioactive molecules from physiologically conditioned human cells into a stable biologic drug product. …

5 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

LIVING CURES Prokarium is pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Biotechnology, Vaccines, Oral delivery, Immunology, Synthetic Biology, Oncology, Microbial Immunotherapy, and Immunotherapy

125 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

155 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

First-in-class ADCs tailor designed to attack advanced cancer Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

82 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We believe the only way to discover better, life-changing drugs is by seeing diseases in action, not guessing them. That’s why at Anima Biotech, we’ve built the AI platform that thinks, sees, and learns biology at the core of disease mechanisms, inside real patient-derived cells. Anima Biotech is a TechBio pioneer, transforming target and drug discovery with Lightning.AI - the first Visual Biology loop where Computational and Experimental AI agents iteratively think, see, and learn disease pathways, turning the undruggable into tomorrow’s therapies. Lightning.AI runs two AIs in one discovery loop - Computational AI that thinks of thousands of hypotheses …

48 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology A.I.

Targeting protein interactions for health Founded in 2023, TheraPPI Bioscience is a biotechnology company whose science originates from the CRCL (Centre de Recherche de Cancérologie de Lyon, France). We modify protein interactions to offer treatments where current therapies fail. Our approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases protein-protein interaction, PPI, small molecule, therapeutics, oncology, and rare disease

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Targeting diseases at their molecular roots Vivoryon is focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. The mechanisms of action underlying our approach enables us to target a variety of disease areas with high medical need. With historic roots in diabetes research and development as well as neurodegenerative disorders, Vivoryon’s focus …

Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Preventing deaths from cancer metastases Infinitopes is a pioneer in precision immunomics medicines. A Cancer Research UK (CRUK)-led biotech spinout from Oxford University, we are empowering the immune system to fight cancer metastases with unique, de novo antigen discovery technologies, innovative high efficiency vectors and intelligent clinical trial design. Our mission is to significantly enhance patient survival.

294 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Multiomics research for precision medicines Platinum Discovery offers a cutting-edge Tumour-to-Target Platform, specialising in cancer vaccine development through the identification of tumour-specific neoantigens. We provide a comprehensive, end-to-end drug discovery pipeline, supporting clinical trial research and translational science for patient samples. Our multidisciplinary team brings together expertise in biology, clinical sciences, multi-omics technologies, bioinformatics, and computational sciences, enabling a deep understanding of the biological processes critical to drug development. We excel at integrating diverse scientific domains to deliver holistic, innovative solutions. With extensive experience in designing and managing complex research programmes, we assemble tailored teams of experts, drawing on our …

112 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leveraging science and innovation to accelerate the development of next-generation antibody therapeutics. AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. We specialize in next-generation antibody therapeutics through our two unique and proprietary technologies, SeqitopeTM and Opti-mAbTM, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Our team is made up of highly qualified experts, all with PhDs in relevant fields. Our mission is to innovate and solve unmet needs …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source. Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.

48 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Actor of change Immune Biosolutions is a clinical-stage biotechnology company specializing in the discovery and engineering of avian and human antibodies for therapeutic applications. Utilizing cutting-edge technologies, we develop custom immunotherapeutic agents. Our discovery platform efficiently targets complex proteins and generate powerful, specific, and innovative antibodies. Additionally, our antibody production capability allows us to advance our own discovery programs in cancer and autoimmune diseases into the early phases of clinical development. Anticorps, Custom antibody development, Antibody, Développement sur mesure de génération d'anticorps, IgY, Chicken, Poulet, ELISA, Therapeutic Antibodies, Recombinant Antibodies, Humanized Antibodies, GPCRs, and Oncology

94 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ligandal is developing precision molecular therapeutics and targeted delivery technologies. Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, …

24 similar entities Type: Startup Activities: biotech deeptech healthtech nanotech Technologies: Synthetic Biology

We give access to the pulse of life Unlocking the Future of Cell Screening with Groundbreaking Innovation MicroOmix is a pioneering startup powered by patented technology from the CNRS and the University of Strasbourg, setting a new standard in high-throughput cell screening. Our cutting-edge platform analyzes cells based on the molecules they secrete, with a level of precision and resolution that is unrivaled. Secreted molecules are at the heart of critical biological processes—driving immune responses, cell migration, tissue regeneration, and differentiation. Emerging research reveals their pivotal role in disease progression and therapeutic effectiveness, but until now, accessing these insights has …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science for cure. NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Therapeutic Immune Design, Centre for Molecular Medicine at Karolinska Institute, Stockholm, Sweden. Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system. Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy. Biopharmaceutical company, Immunotherapy, and Immuno-oncology

99 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Genewity is a pioneering biotech start-up focused on advanced thymus-driven therapies for immune reconstitution. Supported by the extensive business expertise of our management and advisors, we are at the forefront of developing and commercialising breakthrough therapies. With over 150 years of combined experience in immunology and gene therapy, our team is uniquely positioned to drive advancements in the field.

275 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your trusted partner for innovative, end-to-end antibody services At FairJourney Biologics, we specialize in cutting-edge antibody discovery and development, offering end-to-end solutions that fast-track your research. With over a decade of expertise, our innovative technologies and seasoned team have successfully advanced 14 antibodies to clinical stages. Our adaptable partnership model empowers projects of any scale, fostering collaboration and breakthrough innovation. Whether you're in early-stage research or development, we deliver tailored, high-quality antibodies designed to meet your specific needs. Join us in revolutionizing therapeutic discovery and making lasting impacts on global healthcare. Monoclonal antibodies, Antibody humanization, Antibody production, Antibody affinity maturation, …

76 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics …

126 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Allogeneic Cell Therapy Platform that Leverages Natural Platelet Biology PlateletBio is an allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a cell therapy empowered to tackle previously unmet medical challenges. biotechnology, platelets, and drug discovery

124 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We Embrace the Challenge in Science Dompé farmaceutici is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up. We can turn transformative breakthroughs into treatments because we have the right qualities and capabilities to deliver new drugs. Our 160,000 square meter R&D and production site in L’Aquila, Italy, is the heart of Dompé. Here, we conduct vital research, and produce and distribute our primary care and …

84 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Toward the next generation of gene therapy. Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. Toward life-changing therapies, and brighter …

88 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology